Welcome to our dedicated page for Stryker SEC filings (Ticker: SYK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Stryker Corporation (NYSE: SYK) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual and quarterly reports, and other materials that describe Stryker’s financial condition, governance and material events as a global medical technologies company focused on MedSurg, Neurotechnology and Orthopaedics.
Current reports (Form 8-K) play a central role in Stryker’s disclosure practices. For example, the company has filed 8-Ks to furnish press releases announcing second and third quarter 2025 operating results, detailing net sales, segment performance and earnings metrics. Another Form 8-K dated December 4, 2025 reports leadership changes, including the appointment of a President and Chief Operating Officer and a new Group President, Orthopaedics, and summarizes related compensation arrangements.
Through its SEC filings, Stryker also identifies its registered securities and capital structure. Filings list the company’s common stock, traded on the New York Stock Exchange under the symbol SYK, along with multiple series of senior unsecured notes with different maturities that are also listed on the NYSE. These disclosures help investors understand the instruments available for investing in Stryker and the company’s obligations under its notes.
On Stock Titan, Stryker’s filings are updated in step with new submissions to the SEC’s EDGAR system. AI-powered tools summarize key points from lengthy documents, helping readers quickly identify items such as results of operations, leadership changes, segment commentary and descriptions of registered securities. Users can review Stryker’s historical and recent filings to track how the company reports on its MedSurg, Neurotechnology and Orthopaedics businesses, financial performance and governance over time.
Ronda E. Stryker filed Amendment No. 8 to update her beneficial ownership in Stryker Corp. She reports beneficial ownership of 15,223,331 common shares, representing 4.0% of the outstanding class. Of these, she has sole voting and dispositive power over 2,235,338 shares and shared power over 12,987,993 shares.
The amendment notes recent activity, including exercising 4,570 options on January 14, 2026, a gift of 655,800 shares initiated on February 2, 2026, a sale of 500,000 shares initiated on February 4, 2026, and a transfer of 42,000 shares on the same date. Stryker indicates she may continue to buy or sell shares over time depending on market conditions and personal considerations.
Stryker Corporation filed an Amendment No. 1 to a prior current report to update investors on a March 11, 2026 cybersecurity incident. After further assessment, the company determined the attack had a material impact on its operations and on financial results for the first quarter of 2026.
Stryker reports that its global manufacturing, commercial, ordering and distribution systems are now fully operational, although the investigation remains ongoing. The company currently believes the incident has not had, and is not reasonably likely to have, a material impact on its 2026 full-year guidance, and plans to discuss first-quarter results and its guidance in more detail when it reports earnings on April 30, 2026.
Stryker Corp Schedule 13G/A amendment shows The Vanguard Group reports 0 shares beneficially owned and 0% of the class as of this filing. The filing states an internal realignment effective January 12, 2026 led certain Vanguard subsidiaries to report beneficial ownership separately; Vanguard says it no longer is deemed to beneficially own those subsidiary holdings.
The form is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026. The filing reiterates Vanguard-managed accounts retain rights to dividends and proceeds for reported securities.
Stryker Corp President and COO Spencer S. Stiles reported routine equity compensation activity. On March 21, 2026, dividend equivalents tied to previously earned performance stock units vested, and 430 Dividend Equivalents were exercised and settled into 430 shares of Common Stock.
To cover related tax obligations, 6,690 shares of Common Stock were disposed of at $335.67 per share through share withholding, not an open-market sale. After these entries, Stiles directly holds 77,634 Common Stock shares and indirectly holds 1,670 shares through a 401(k) plan, indicating a continuing substantial ownership position.
Stryker Group President James Andrew Pierce reported routine equity compensation activity tied to previously earned performance stock units. On March 21, 2026, 430 dividend equivalent units were converted into an equal number of Stryker common shares, while 7,807 shares were delivered to cover tax obligations. Following these transactions, Pierce holds 80,869 Stryker common shares directly, plus indirect holdings of 712 shares through Son GP, 713 shares through Son AP, and 1,595 shares through a 401(k) account.
Stryker Group President Viju Menon reported routine equity compensation activity. Dividend equivalents tied to previously earned performance stock units were exercised into 269 shares of Common Stock, while 4,718 shares were withheld at $335.67 per share to cover tax obligations. Following these entries, he directly holds 17,382 shares, plus 198 shares indirectly through a 401(k).
Stryker Corporation Chair and CEO Kevin Lobo reported routine equity compensation activity tied to previously earned performance stock units. He exercised dividend-equivalent rights into 1,452 shares of common stock and, in a separate transaction, 26,492 shares were withheld at $335.67 per share to cover tax obligations. After these transactions, he holds 222,231 common shares directly and 721 shares indirectly through a 401(k) plan.
Stryker Corp VP and Chief Legal Officer Robert S. Fletcher reported compensation-related stock activity tied to prior performance awards. On March 21, 2026, he exercised 225 dividend equivalent units linked to previously earned Performance Stock Units, receiving an equal number of Stryker Common Stock shares at no cost.
On the same date, 3,384 Common Stock shares were disposed of at $335.67 per share to cover tax obligations, a non-market transaction coded as tax withholding. After these entries, Fletcher directly holds 15,126 Common Stock shares and indirectly holds 162 shares through a 401(k) plan.
Stryker Corp vice president and Chief HR Officer M. Kathryn Fink reported routine equity compensation activity. Dividend-equivalent rights tied to previously earned performance stock units were exercised into 150 shares of common stock on March 21, 2026, and settled at no exercise price.
On the same date, 2,064 shares of common stock were disposed of at $335.67 per share to cover tax obligations, leaving Fink with 16,637 shares of Stryker common stock held directly. Additional indirect holdings include 422 shares held through a 401(k) plan and 177 shares held by the 2023 Mary Fink Living Trust.
Stryker Corporation VP and Chief Financial Officer Preston Wendell reported a routine tax-related share disposition. On the reported date, 204 shares of common stock were withheld at $335.67 per share to satisfy tax obligations, a non-market transaction. After this, he held 6,498 shares directly and 288 shares indirectly through a 401(k) plan, which includes shares acquired under the ESPP and PIA plans as of December 31, 2025.